Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Registered Phase 3 interventional trial (recruiting). Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Registered clinical trial record on ClinicalTrials.gov (NCT07575399). This describes a planned, ongoing, or completed study — it is NOT peer-reviewed results. Status: recruiting. Study type: interventional. Phase: Phase 3. Sponsor: Amgen. Conditions: Obesity or Overweight. Interventions: Maridebart Cafraglutide. Summary: Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight. Primary outcome measures: Percent Change from Baseline in Body Weight at Week 68. Eligibility: Inclusion Criteria: * Body Mass Index (BMI) ≥ 25 at screening. * Weight loss of ≥ 10% on weekly GLP-1 RA. * Stable body weight. * Stable dose of GLP-1RA. * Stable gastrointestinal (GI) tolerability. * Contraception for females. * Willingness to follow trial procedures for the duration of the trial. Exclusion Criteria: * Obesity induced by other endocrine disorders (ex: Cushing's syndrome). * Previous or planned surgical, endoscopic or device-based treatment for obesity. * History of malignancy. * Type 1/Type 2 diabetes mellitus (DM). * Family or personal history of medullary thyroid cancer. * Previous participation in a Maridebart Cafraglutide trial.
This is a registered clinical-trial record from ClinicalTrials.gov — a description of a planned, ongoing, or completed study, not peer-reviewed results. Listing on ClinicalTrials.gov does not mean the study has been evaluated by the U.S. Federal Government, nor does it imply endorsement or that the intervention is safe or effective.
Educational summary of published research — not medical advice. License: public-domain. Full text is shown only where licensing permits.